We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Vernon Sondak

Vernon K Sondak MD

Chair, Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida; Professor, Departments of Oncologic Sciences and Surgery, University of South Florida Morsani College of Medicine, Tampa, Florida

Dr Sondak is Chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. He holds the Richard M. Schulze Family Foundation Distinguished Endowed Chair in Cutaneous Oncology there, and is also a Professor in the Departments of Oncologic Sciences and Surgery at the University of South Florida Morsani College of Medicine.  Since 2004, when he came to Tampa, the Cutaneous Oncology Clinic at Moffitt has grown into one of the largest multidisciplinary treatment centers for melanoma and other skin cancers in the world, now seeing well over 2000 new patients each year.  Dr. Sondak serves as Principal Investigator of the Moffitt Skin SPORE, a major NCI-funded “team science” grant conducting translational research in melanoma and other cutaneous malignancies.  His research interests include surgical treatment of melanoma in adults and children; surgical treatment of Merkel cell carcinoma and other rare cutaneous tumors, including dermatofibrosarcoma protuberans; adjuvant and neoadjuvant therapy of melanoma; and evaluation of new therapies for patients with localized or disseminated melanoma.  Dr. Sondak has been a leader in studies of surgical treatment of melanoma and other cutaneous malignancies, particularly in the application of sentinel lymph node biopsy and lymph node dissection to the staging and treatment of melanoma and Merkel cell carcinoma, and has been instrumental in training many surgical oncologists in these techniques over the years. 

A graduate of Boston University School of Medicine, Dr. Sondak did his surgical training at the University of California Los Angeles. Prior to joining Moffitt in 2004, Dr. Sondak was a Professor of Surgery in the Division of Surgical Oncology at the University of Michigan.  Dr. Sondak has received numerous awards, including the Golden Scalpel Award (Outstanding Chief Resident) from the UCLA Division of General Surgery, a Distinguished Alumnus Award from Boston University School of Medicine, the William W. Coon Award for Outstanding Faculty Teaching from the University of Michigan Section of General Surgery, and the Rays of Hope Leadership Award from the Shade Foundation of America, devoted to skin cancer education and prevention for children.  He is a member of the National Cancer Institute’s Board of Scientific Counselors for Clinical Sciences and Epidemiology, the group responsible for peer review and oversight of the NCI’s intramural research program.  He is also North American Vice President of the Melanoma World Society, and a member of the Lancet Oncology International Advisory Board, as well as an external advisor to several SPORE grants at other US institutions.

Dr Sondak is the author or coauthor of 404 articles in peer-reviewed publications, 221 abstracts, and 8 books and 77 book chapters.  He has served as a peer reviewer for manuscripts in over 50 different journals, including virtually all of the most prestigious surgery, oncology and dermatology journals.

Disclosures

Disclosure Information 2019: Vernon K. Sondak, MD

Advisory Board Relationships

            Merck, Bristol-Myers Squibb, Novartis, Regeneron

Data Safety Monitoring Boards

Bristol-Myers Squibb, Array, Novartis, Polynoma, Pfizer